NCT06427941 2026-03-18
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
BeOne Medicines
Myeloid Therapeutics
Aptamer Sciences, Inc.
Second Affiliated Hospital of Guangzhou Medical University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School